Links for Keyword: Huntingtons
Follow us on Facebook and Twitter, or subscribe to our mailing list, to receive news updates. Learn more.
STANFORD, Calif. - Stanford University Medical Center researchers have discovered a potential treatment for Huntington's disease. By enhancing the brain's natural protective response to the disease, researchers were able to alleviate the uncontrollable tremors and prolong the lives of mice with a neurological disorder that mimics Huntington's. Their finding suggests that a similar treatment strategy may be effective in humans. "This is exciting because it has implications for therapy," said Lawrence Steinman, MD, professor of neurological sciences and pediatrics and senior author of the study, published in the February issue of Nature Medicine. Huntington's disease is a hereditary disorder characterized by memory loss, abnormal movement and premature death. It affects 1 in 10,000 people, and children with an affected parent have a 50 percent chance of developing the disease.
by Roberta Friedman So many diseases that destroy the aging brain have been linked with clumping proteins, yet the debate over cause and effect continues. Presented here today, recent findings bolster evidence that protein aggregates themselves may not damage nerve cells directly, or produce the clinical signs. The fibers and where they first appear cause the problem, contend researchers at the University of California, who presented a new way to visualize the process microscopically. Although diseases such as Huntington's and Alzheimer's are described collectively as neurodegeneration, some of their dysfunction may be due to the toxic effects of soluble forms of the affected proteins, says Steven Finkbeiner, assistant investigator at the Gladstone Insitute of Neurological Disease at UC San Francisco. They may actually precede the deposition of the protein in the brain as clumps. © Elsevier Science Limited 2000
The cells were injected through a drill-hole in the skull A BBC documentary has followed the first ever UK operation using transplanted foetal brain cells in an attempt to halt a devastating disease. Huntington's Disease is caused by a single faulty gene, and causes gradual and invariably fatal decline. Parents who carry it have a 50% chance of passing it on to their children.
Trial drugs for Huntington's Disease inconclusive in
A large-scale clinical trial that tested the ability of the investigational drugs remacemide and Coenzyme Q10 to slow the progression of Huntington's disease showed that neither drug resulted in any significant improvement for the patients. Although after one year of treatment, the disease seemed to progress more slowly in patients treated with Coenzyme Q10, the investigators say that overall the results are inconclusive as to whether there is real benefit from this drug. The study is published in the August 14, 2001, issue of Neurology.* "A Randomized, Placebo-Controlled Trial of Coenzyme Q10 and Remacemide in Huntington's Disease (CARE-HD);" Huntington Study Group; Neurology Aug. 14, 2001; 57: 397
Huntington's disease: Italian discovery may suggest a new approach for developing therapies Like a good parent, a protein called huntingtin helps to safeguard key nerve cells in the brain. When the huntingtin protein is defective, however, certain neurons can become damaged, resulting in Huntington's Disease, a debilitating and fatal form of brain degeneration characterized by physical, mental and emotional disturbances. The discovery of one of normal huntingtin's exact functions within the brain--to be published online by the journal, Science, as part of the Science Express web site on 14 June--suggests novel therapeutic strategies to fight the disorder.
Understanding Huntington's Disease Researchers implicate a second protein in the debilitating illness Researchers are inching ever closer to a treatment for the inherited neurodegenerative disorder Huntington's disease (HD). Following close on the heels of recent optimistic reports on fetal cell implants1,2 comes a report from Johns Hopkins University that sheds light on a possible mechanism of neuronal destruction in HD.3 The work reveals possible new drug targets. Legendary folksinger Woody Guthrie's fight with HD brought the disease into the public eye in the 1960s. Today, some 30,000 people in the United States are affected by the late-onset, autosomal dominant condition. Early symptoms--such as anger or depression, repetitive fidgety movements, and a clumsiness and tendency to fall--may go unnoticed for years. Neurological deterioration, reflecting cell death in the brain's striatum, typically continues for 15 to 20 years. The Scientist 15:14, Apr. 16, 2001 © Copyright 2001, The Scientist, Inc. All rights reserved.